Suven Pharma Q2 net rises 10%, inventory de-stocking impacts revenue

November 09, 2023 09:57 pm | Updated 09:57 pm IST - HYDERABAD

Contract development and manufacturing operations (CDMO) company Suven Pharmaceuticals (SPL), that was acquired recently by PE firm Advent International, reported consolidated net profit for the September quarter increased 10% year-on-year to ₹79.56 crore.

The higher net profit came on a 17% decline in revenue from operations to ₹231 crore (₹278.4 crore). “Q2 revenues have been soft due to inventory de-stocking globally in specialty chemicals,” SPL managing director V.Prasada Raju said.

CEO Sudhir Kumar Singh said “we have initiated building out the commercial engine, hired key leaders for the U.S. and EU markets and in the process of building the team below them. Our focus is to continue scaling existing business... while also on winning new business.”

In the last week of September, Advent International said it has completed acquisition of 50.1% stake in Suven Pharma at the agreed price of ₹495 per share. An open offer for the remaining 26% of stake will be triggered within stipulated timelines, it had said.

In a release on the second quarter results, Executive Chairman Annaswamy Vaidheesh said the transition to the new management has been completed smoothly. “We have augmented the senior leadership with proven track record and deep experience in the space. Our team has met most customers in person... feedback has been very encouraging. The team also interacted with all our 1,200-plus employees and is focused on retention of the existing culture and ethos of the company,” he said.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.